Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
civacir
- Development stage
- Unknown
- Lead developer
- Biotest
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Civacir is a human polyclonal immune globulin product enriched with antibodies against the hepatitis C virus (HCV). It is designed to prevent recurrence of HCV infection in patients undergoing liver transplantation due to HCV-induced end-stage liver disease. Civacir is derived from pooled plasma of donors with high titers of anti-HCV antibodies, resulting in a broad spectrum of neutralizing activity against multiple HCV genotypes and escape variants. Its mechanism of action involves direct neutralization of circulating HCV particles, thereby reducing the risk that the new liver graft will become re-infected after transplantation. Civacir has been evaluated in phase III clinical trials for its efficacy and safety in this setting and has received orphan drug status and fast track designation from regulatory authorities[1][2][5][6].
- Brand names
- Civacir
- Other names
- hepatitis C immune globulinHCIGhepatitis C immune globulin intravenous (human)
02
Targets
HCV E1 (Hepatitis C virus envelope glycoprotein E1)
Beyond the preview
Go deeper on civacir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on civacir.